| miR-378378
|
non-small-cell lung cancer |
prognostic |
| miR-323-3p, miR-1468-3p, miR-5189-5p, and miR-651359379
|
non-small-cell lung
cancer |
prognostic; osimertinib therapy management |
| miR-486-5p and miR-146a-5p380
|
non-small-cell lung cancer |
early diagnosis |
| miR-375-3p381
|
non-small-cell lung cancer |
therapeutic |
| miR-433382
|
non-small-cell lung cancer |
therapeutic |
| miR-148a383
|
breast cancer |
prognostic |
| miR-423, miR-424, let7-i, and miR-660384
|
breast cancer |
diagnostic |
| miR-567385
|
breast cancer |
therapeutic; reversing trastuzumab resistance |
| miR-9 and miR-181a386
|
breast cancer |
therapeutic; expanding early myeloid-derived suppressor cells
(MDSCs) |
| miR-423-3p387
|
prostate cancer |
prognostic; castration resistance |
| miR-16-5p, miR-451a, miR-142-3p, miR-21-5p, and miR-636388
|
prostate cancer |
prognostic; metastasis |
| miR-125a-5p and miR-141-5p389
|
prostate cancer |
diagnostic |
| miR-375 and miR-451a390
|
prostate cancer |
diagnostic |
| miR-143 (from cancer tissue)391
|
prostate cancer |
therapeutic |
| miRNA-92a-1-5p392
|
prostate cancer |
therapeutic |
| miR-24-3p393
|
oral squamous cell carcinoma |
diagnostic |
| miR-130a394
|
oral squamous
cell carcinoma |
diagnostic and prognostic |
| miR-30a395
|
oral squamous cell carcinoma |
therapeutic;
cisplatin sensitivity |
| miR-130b-3p396
|
oral squamous
cell carcinoma |
therapeutic |
| miR-139-3p383
|
colorectal cancer |
diagnostic |
| miR-126, miR-1290, miR-23a, and miR940397
|
colorectal
cancer |
diagnostic |
| miR-106b-3p398
|
colorectal cancer |
therapeutic |
| miR-221/222399
|
colorectal cancer |
therapeutic |
